is extended-release injectable buprenorphine not recommended in moderate or severe liver impairment?
“extended release injections. It's not recommended with moderate or severe hepatic impairment, again, because the formulation doesn't allow for rapid dose adjustment.”
a guest, Dr. Kevin A. Severino, lecturer on addiction psychopharmacology said on Psychopharmacology and Psychiatry Updates, 2026-11-13, at 03:58. hear it in context →
the episode: Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents (at 03:58). we link the show's own page; we do not re-host audio.
first, the part that holds
The claim holds. Both extended-release buprenorphine injections sold in the US have current FDA labeling that says "moderate to severe hepatic impairment: not recommended". Both labels give the reason the speaker gave: the long-acting depot means a dose change does not quickly change buprenorphine levels in the blood.
what we found when we went and looked
We read the current DailyMed prescribing information for both US extended-release buprenorphine injections: the weekly/monthly product (revised 12/2025) and the monthly product (revised 2/2025, DailyMed entry updated july 2026). Both highlights sections say "moderate to severe hepatic impairment: not recommended". The warnings sections say patients with pre-existing moderate to severe hepatic impairment "are not candidates for treatment", because "adjustments to dosages ... are not rapidly reflected in plasma buprenorphine levels". In US labeling this is a warning, not a formal contraindication; the only contraindication listed is hypersensitivity. The recommendation also rests on liver-impairment data from under-the-tongue (sublingual) buprenorphine, because neither injection has been studied in hepatic impairment. European labeling for the weekly/monthly product draws the line differently: severe impairment is a formal contraindication there, and moderate impairment calls for caution only.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| Labeling for extended-release injectable buprenorphine says it is not recommended in moderate or severe hepatic impairment | confirmed | Both US labels list 'Moderate to Severe Hepatic Impairment: Not recommended' in their highlights. The weekly/monthly product (section 5.14 and 8.6) and the monthly product (section 5.15) both say patients with pre-existing moderate to severe hepatic impairment 'are not candidates for treatment.' Limitation: this is a warning and precaution, not a section 4 contraindication. US contraindications list only hypersensitivity. [1][2] |
| The reason is that the formulation does not allow rapid dose adjustment | confirmed | Both labels say: 'Because of the long-acting nature of the product, adjustments to dosages ... are not rapidly reflected in plasma buprenorphine levels.' The weekly/monthly label adds that 'buprenorphine levels cannot be rapidly decreased.' The speaker paraphrased the label's own rationale closely. [1][2] |
| The hepatic recommendation is based on studies of the injectable products themselves | false | Both US labels say the effect of hepatic impairment on the injection's pharmacokinetics 'has not been studied.' The recommendation is extrapolated from a transmucosal buprenorphine study. In that study, plasma levels were higher and half-life longer in moderate and severe impairment, but not in mild impairment. The speaker did not claim otherwise; this row covers a common assumption. [1][2] |
| The same moderate-and-severe rule applies in every regulator's labeling | overstated | The European product information for the weekly/monthly prolonged-release injection says buprenorphine 'should be used with caution in patients with moderate hepatic impairment.' It lists 'severe hepatic impairment' as a contraindication in section 4.3. That is stricter than the US label for severe impairment and looser for moderate. The speaker's statement fits US labeling, not every jurisdiction. [3] |
both directions
for the speaker: The wording and the reasoning both match the FDA labels. Both US injections carry 'moderate to severe hepatic impairment: not recommended' in the highlights and say patients with pre-existing moderate to severe impairment 'are not candidates for treatment.' Both explain this the way the speaker did: dose changes to a long-acting depot are 'not rapidly reflected in plasma buprenorphine levels.' Both labels also say that patients who develop moderate to severe impairment during treatment should be monitored for several months for signs of toxicity or overdose. That follows from the same slow-clearance logic.
against: Nothing in the US record contradicts the claim. Three nuances matter for a reader. First, in US labeling this is 'not recommended' language under warnings and specific populations, not a formal contraindication. Second, neither injection has been studied in people with hepatic impairment; the caution is extrapolated from transmucosal buprenorphine data. Third, the claim is US-specific. The European product information for the weekly/monthly injection contraindicates use in severe impairment and advises only caution in moderate impairment. A listener outside the US could find their local label worded differently.
what this cannot say
The labels say what the regulator approved. They do not show how hepatic impairment changes buprenorphine levels from these depots, because that has not been studied. Labels also say nothing about outcomes in people with liver disease who receive the injection anyway. We read the US labels through DailyMed's web pages, in excerpts, and did not open the full XML files. We checked one European product information document and did not survey other regulators, such as Australia's TGA, Health Canada or the UK's MHRA. Labels are revised over time; this reflects versions current in november 2026.
the medication pages behind this check
sources, each one fetched and read
- DailyMed (NLM). Buprenorphine extended-release injection for subcutaneous use, weekly and monthly, prescribing information. Revised 12/2025. setid 5d8a8fd0-8619-422a-a664-d1d2e8970f48 What we read there: Highlights: 'Moderate to Severe Hepatic Impairment: Not recommended.' Section 5.14: 'Because buprenorphine levels cannot be rapidly decreased, patients with pre-existing moderate to severe hepatic impairment are not candidates for treatment'; 'The effect of hepatic impairment on the pharmacokinetics ... has not been studied.' Fetched 2026-11-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d8a8fd0-8619-422a-a664-d1d2e8970f48
- DailyMed (NLM). Buprenorphine extended-release injection for subcutaneous use, monthly, prescribing information. Revised 2/2025; DailyMed entry updated July 27, 2026. setid 6189fb21-9432-45f8-8481-0bfaf3ccde95 What we read there: Highlights: 'Moderate to Severe Hepatic Impairment: Not recommended.' Section 5.15: 'Because of the long-acting nature of the product, adjustments to dosages ... are not rapidly reflected in plasma buprenorphine levels'; patients with pre-existing moderate to severe hepatic impairment 'are not candidates for treatment.' Section 4 contraindications list only hypersensitivity. Fetched 2026-11-14 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6189fb21-9432-45f8-8481-0bfaf3ccde95
- European Medicines Agency. Buprenorphine prolonged-release solution for injection (weekly and monthly), EPAR product information, summary of product characteristics, sections 4.2 and 4.3 What we read there: Section 4.2: 'Buprenorphine should be used with caution in patients with moderate hepatic impairment ... In patients with severe hepatic impairment, the use of buprenorphine is contraindicated.' Section 4.3 lists 'Severe hepatic impairment' among contraindications. Fetched 2026-11-14 (HTTP 200). https://www.ema.europa.eu/en/documents/product-information/buvidal-epar-product-information_en.pdf
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam